Skip to main content
Premium Trial:

Request an Annual Quote

Bielefeld University's CeBiTec Purchases New Hardware from Active Motif's TimeLogic

Premium

TimeLogic, an Active Motif subsidiary, said this week that the Center for Biotechnology (CeBiTec) at Bielefeld University has added the latest version of its J-series field programmable gate array hardware to its suite of computational tools.

This purchase adds to an existing DeCypher system at CeBiTec that supports research into gene and protein functions. TimeLogic’s DeCypher systems use a combination of field programmable gate array-based PCIe accelerator cards and servers to run implementations of Blast, Smith-Waterman, hidden Markov model, and gene modeling algorithms.

Michael Murray, the sales & marketing manager for TimeLogic products at Active Motif, said in a statement that the newly added hardware "will run Tera-BLAST, our accelerated BLAST implementation, many hundreds of times faster than the software-only version." It will also speed up analysis workflows for things like genome annotation, comparative genomics, and metagenomics.

The financial details of the purchase were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.